Achieve Life Sciences, Inc.
ACHV- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000949858
In the last 90 days, Achieve Life Sciences, Inc. insiders filed 0 open-market purchases and 1 sale; 111 institutions reported holding it in 13F filings for Q2 2026, worth $539.5M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $175.2K in total
- 1
- 13F holdersQ2 2026, +31 vs. previous quarter
- 111
- 13F valueReported value at the end of Q2 2026
- $539.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ACHV, Q2 2026
No superinvestor reported holding ACHV at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Achieve Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Stewart Richard AlistairDirector | SSale | −20.6K | $8.49 | −$175.2K | −9.0%208.2K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Oki Mark KChief Financial Officer | SSale | −50.1K | $2.92 | −$146.2K | −28.1%127.9K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Stewart Richard AlistairChief Executive Officer | SSale | −129.5K | $2.92 | −$378.1K | −36.1%228.9K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Wan JerryPrincipal Accounting Officer | SSale | −14.1K | $2.77 | −$39.0K | −30.1%32.7K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | King Thomas BraxtonDirector | SSale | −139.9K | $2.77 | −$387.4K | −30.7%315.1K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Jacobs CindyPresident & CMO | SSale | −27.6K | $2.77 | −$76.5K | −19.3%115.6K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Xinos JaimeChief Commercial Officer | SSale | −20.9K | $2.77 | −$57.8K | −21.9%74.4K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Oki Mark KChief Financial Officer | PPurchase | +10.0K | $2.89 | +$28.9K | New position10.0K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Stewart Richard AlistairChieve Executive Officer | PPurchase | +10.0K | $2.86 | +$28.6K | +19.7%60.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Stewart Richard AlistairExecutive Chairman | PPurchase | +10.0K | $4.59 | +$45.9K | +35.1%38.5K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Achieve Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,614,836 | $49.7M | 1.08% | +7,614,836 | New |
| TPG GP A, LLC | 6,877,580 | $44.9M | 0.90% | +6,877,580 | New |
| venBio Partners LLC | 5,914,720 | $38.6M | 7.44% | +5,914,720 | New |
| Logos Global Management LP | 5,425,000 | $35.4M | 1.53% | +5,425,000 | New |
| BlackRock, Inc. | 5,272,017 | $34.4M | 0.00% | +4,832,657+1,099.9% | Added |
| Franklin Resources Inc | 4,953,220 | $32.3M | 0.01% | +584,027+13.4% | Added |
| Paradigm Biocapital Advisors LP | 4,951,856 | $32.3M | 0.61% | +4,951,856 | New |
| Vanguard Capital Management LLC | 4,140,812 | $27.0M | 0.00% | +1,936,098+87.8% | Added |
| Propel Bio Management, LLC | 4,034,018 | $26.3M | 13.79% | +247,593+6.5% | Added |
| Marshall Wace, LLP | 3,770,313 | $24.6M | 0.02% | +2,751,032+269.9% | Added |